Trials / Completed
CompletedNCT01455441
The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes
Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Tina Vilsboll · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to investigate the effects of physical training in patients with type 2 diabetes during treatment with the GLP-1 receptor agonist liraglutide (Victoza®) in a 16-weeks double-blinded, randomized placebo-controlled clinical trial. Hypothesis: Physical training leads to better metabolic control in type 2 diabetic patients when training is combined with liraglutide (Victoza®) treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Training and liraglutide | |
| OTHER | Training and placebo |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-06-01
- Completion
- 2014-06-01
- First posted
- 2011-10-20
- Last updated
- 2015-05-29
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01455441. Inclusion in this directory is not an endorsement.